IFF completing its pharma solutions divestiture wasn't a retreat—it was a strategic recalibration that most chemical companies get wrong. I say that as someone who spent four years on the pharma supply side before moving into specialty chemicals. The difference between those who win and those who bleed out is knowing when to stop treating a business unit like a pet project.
Let me give you the short version: if you're in pharma solutions and you can't hit a 13x EBITDA multiple, you're probably holding an anchor. IFF's exit (announced as completed in Q4 2024) tells you everything about where value actually lives in this industry. Here's what my mistakes taught me.
Why I Initially Dismissed the Divestiture
Back in early 2023, when rumors started circulating about IFF shopping its pharma solutions division, I thought it was a mistake. My reaction? “They're cutting off a growing arm.” Pharma solutions had been a consistent revenue driver, and I'd seen similar divisions prop up weaker portfolios.
I was wrong. Here's how I know.
In Q2 2023, I was helping a mid-tier contract manufacturer evaluate whether to acquire a similar pharma solutions unit from a European competitor. The numbers looked good on paper: $45M revenue, 18% margins, growing 7% YoY. But when we dug into the fixed capital requirements and the regulatory tail, the EBITDA multiple dropped to 8.5x. The acquirer walked. Six months later, that unit's margins compressed to 12% as raw material costs shifted and two major contracts went to 90-day payment terms.
IFF reportedly sold at around 13x EBITDA. That's not just good—it's a signal that they timed the exit before the segment's natural ceiling kicked in. (Source: industry analyst reports, December 2024; verify current transaction details with IFF investor relations.)
The Question Nobody Asks: What Does 'Strategic Fit' Actually Mean?
Everyone talks about synergy. Nobody talks about capital efficiency. The question isn't whether a pharma solutions division makes money. It's whether that capital generates better returns elsewhere.
I learned this the hard way in Q3 2022. I'd championed an internal project to expand our specialty chemical sampling program—you know, the "give away samples to land big accounts" strategy. The board approved $120K for sample production. But we didn't calculate what that capital could have done if deployed into our industrial coatings line instead. We got $180K in new orders from the samples. Sounds good, right?
Except the coating line, which we underfunded by that same $120K, missed a window to secure a $2M contract with a major automotive supplier. The competitor who got that contract? They'd spent their capital on production capacity, not samples.
See the pattern? Capital isn't about what you spend. It's about what you don't earn somewhere else.
What DLC Coating Taught Me About Specialization
Speaking of coatings—you'd think I'd have learned earlier. I first encountered DLC (diamond-like carbon) coating in 2021 when a client in precision tooling asked if we could supply it. I said yes without understanding the technical requirements. The result? A $3,200 order where 60% of the coated parts failed adhesion testing. Wasted material, wasted time, and a very unhappy customer.
What is DLC coating? In simple terms, it's an amorphous carbon coating that mimics diamond's hardness—typically 10-30 GPa hardness, with a coefficient of friction around 0.1. It's used in cutting tools, automotive components, and medical devices where wear resistance matters. (Reference: ASTM F2997-14 standard for DLC coating characterization.)
The lesson: specialization matters. IFF's divestiture tells me they recognized that pharma solutions, while profitable, required a different operational DNA than specialty chemicals. The coatings client? I should have referred them to a specialist. Instead, I tried to be everything to everyone. Cost me $3,200 and a relationship.
IFF made the opposite choice. They specialized. (Should mention: they still retain some pharma-related production, just not the full solutions vertical. The divestiture covered the full-service CDMO-like offerings, not isolated API production.)
EPDM Coatings: The 'Good Enough' Trap
Another thing I've messed up: assuming a general solution works for a specific problem. EPDM coatings and butyl liquid rubber are a classic example.
EPDM (ethylene propylene diene monomer) is a synthetic rubber known for weather resistance—UV stability, ozone resistance, operating range from -40°C to 120°C. Butyl rubber, on the other hand, excels at gas impermeability. They're not interchangeable.
In early 2024, a client asked for a liquid-applied rubber coating for a roofing application. I recommended an EPDM-based solution because that's what we stocked. It failed within 18 months because the client needed the lower gas permeability of butyl rubber—their building had a chemical process underneath that produced volatile fumes the EPDM couldn't contain. (I should add: we replaced it at our cost. The butyl rubber coating, when properly applied at 0.5-1.5mm thickness, has held up fine.)
The surprise wasn't the technical failure. It was how much the client's trust cost us. We lost a $50K/year account over a $2K mistake.
Why does this matter for IFF? Because product portfolio breadth is only valuable if you know where each product belongs. IFF's specialty chemical portfolio is broad—industrial coatings, biocides, paper coatings—but their divestiture suggests they know exactly where each segment fits. They're not trying to be the EPDM coating for every project.
Propylene Glycol Price Spikes: The Stress Test Nobody Runs
Let's talk about propylene glycol. Prices in 2024 saw significant volatility—up roughly 25% from H1 to H2, driven by propylene oxide feedstock constraints and logistics disruption in the Gulf Coast. (Reference: ICIS pricing data, December 2024; verify current spot prices.)
I'd placed a large propylene glycol order in July 2024 for a pharmaceutical excipient application. Locked in at what I thought was a high price—$1.25/lb. By October, spot prices were at $1.45. I felt smug. Until I realized the contract had a volume commitment that our downstream customer couldn't absorb because their own demand had dropped. We held $18,000 worth of inventory for 5 months.
Here's the thing about commodity chemical pricing: protecting against price risk is useless if you haven't protected against volume risk first.
IFF's divestiture of pharma solutions likely simplified their exposure to these kinds of swings. Pharma-grade propylene glycol requires USP/EP compliance, which adds cost and limits sourcing flexibility. By exiting that vertical, IFF reduces its exposure to pharma-grade commodity volatility while retaining flexibility in industrial-grade chemicals where supply chains are more liquid.
When Is 'Walking Away' the Right Call?
Here's the part most articles won't tell you. IFF's play makes sense if you're a $10B+ chemical conglomerate with multiple business lines to allocate capital. It makes less sense if you're a smaller player with limited diversification.
If you're a mid-size specialty chemical company with 70% of revenue in one vertical, walking away can destroy the company. The key question: does the divested unit command a premium multiple, or is it dragging the parent down? IFF got a premium. They won.
But if you're considering a similar move? Ask yourself three things (took me two failures to learn these):
- Can the unit survive independently? If it needs your balance sheet to function, a sale might fail.
- Is the multiple gap real? Selling a 10x EBITDA unit to save a 8x parent only works if the buyer can synergize the unit to 12x. Otherwise you're just shrinking.
- What's your next move? IFF's divestiture funded reinvestment into industrial coatings and biocides. (At least, that's been my reading of their post-deal statements—check their 2024 annual report for confirmation.)
Dodged a bullet by not trying to replicate their playbook with my own portfolio last year. I was a click away from divesting a modest coating line that would have left us with no growth path. Instead, we optimized it—cut SKUs by 30%, focused on two high-margin applications, and grew margin by 8 points.
The difference? IFF had a clearer path for the capital. I didn't.
That's the real lesson. Not that divestiture is good or bad. But that selling something valuable is only smart if you know exactly what you're buying instead.